TITLE

LABOPHARM GRANTS TRAMDOL MARKETING RIGHTS TO PURDUE PHARMA

PUB. DATE
July 2006
SOURCE
Worldwide Biotech;Jul2006, Vol. 18 Issue 7, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on a definitive licensing and distribution agreement between Labopharm Inc. and Purdue Pharma L.P. for the marketing and distribution of Labopharm's once-daily formulation of the analgesic tramadol in the U.S. Terms of the agreement; Significance of the agreement to the need for more medications to manage pain; Background on the operations of Labopharm Inc.
ACCESSION #
21352198

 

Related Articles

  • LABOPHARM/PURDUE PHARMA SIGN TRAMADOL LICENSING PACT.  // Worldwide Biotech;Oct2005, Vol. 17 Issue 10, p1 

    Reports on a licensing and distribution agreement signed by Labopharm Inc. with Purdue Pharma LP as of October 2005. Terms of the deal; Details of Labopharm's planned commercialization program for once-daily formulation of tramadol; Background information on tramadol.

  • LABOTHERM/PURDUE PHARMA SIGN TRAMADOL PACT.  // Biotech Business;Oct2005, Vol. 18 Issue 10, p8 

    Reports on an agreement entered into by pharmaceutical firm Labopharm Inc. with distributor Purdue Pharma LP, which deals with the distribution of the analgesic tramadol. Views of Labopharm Inc. president and CEO James R. Howard-Tripp on the marketing partnership between the firms; Value of...

  • Pharma: Other News To Note.  // BioWorld Today;5/29/2013, Vol. 24 Issue 102, p12 

    The article offers news briefs on the pharmaceutical industry including the licensing agreement of Grunenthal Group with Purdue Pharma LP and a definitive agreement between Valeant Pharmaceuticals International Inc. and Bausch & Lomb Holdings Inc.

  • BUTRANS.  // MPR - Residents' Edition;Spring/Summer2011, Vol. 20 Issue 1, pA.6 

    The article offers brief information on the opioid analgesic Butrans, which is indicated for the treatment of moderate-to-severe pain, from Purdue Pharma LP.

  • The Industry.  // Pharmaceutical Representative;Nov2005, Vol. 35 Issue 11, p10 

    The article reports on developments relevant to companies in the pharmaceutical industry as of November 2005. Biogen Idec plans a 17% reduction in staffing and sale of its psoriasis drug Amevive as part of a strategic initiative. Labopharm Inc. and Purdue Pharma LP announced a definitive U.S....

  • NEWS HEADLINES: Pain.  // PharmaWatch: CNS;March 2003, Vol. 2 Issue 3, p28 

    Presents news headlines on pain. Positive results achieved by Labopharm Inc. from the clinical trial for the analgesic, tramadol; Formal warning received by Purdue Pharma LP from the U.S. Food and Drug Administration that the press campaign for its OxyContin painkiller did not sufficiently...

  • Rival drug makers battle over pain killer. Spear, Linda // Fairfield County Business Journal;06/05/2000, Vol. 39 Issue 23, p2 

    Reports on the legal dispute between pharmaceutical firms Purdue Pharma LP and Roxane Laboratories Inc. over a patented sustained-release pain control product. Court order in favor of Purdue Pharma's patent position for the drug Oxycondin; Generic reproduction of the drug by rival Roxane...

  • Purdue Pharma L.P. SWOT Analysis.  // Purdue Pharma SWOT Analysis;10/ 1/2014, p1 

    A SWOT analysis of Purdue Pharma L.P. is presented.

  • Court battles continues in painkiller rivalry. Kirsche, Michelle L. // Drug Store News;2/16/2004, Vol. 26 Issue 2, p49 

    Reports that painkiller OxyContin is making headlines again after a judge ruled patents on the drug are unenforceable, opening the floodgates to imminent generic competition. Appeal by Purdue Pharma, the maker of OxyContin; Ruling by U.S. District Judge Sidney Stein on January 5, 2004.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics